Results 11 to 20 of about 2,419 (196)

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS [PDF]

International Journal of COPD, 2022
Mona Bafadhel,1 Klaus F Rabe,2 Fernando J Martinez,3 Dave Singh,4 Patrick Darken,5 Martin Jenkins,6 Magnus Aurivillius,7 Mehul Patel,6 Paul Dorinsky8 1Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and ...
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P   +8 more
doaj   +3 more sources

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD [PDF]

ERJ Open Research, 2020
Inhaled corticosteroid/long-acting β2-agonist combination therapy is a recommended treatment option for patients with chronic obstructive pulmonary disease (COPD) and increased exacerbation risk, particularly those with elevated blood eosinophil levels ...
Nicola A. Hanania, Alberto Papi, Antonio Anzueto, Fernando J. Martinez, Kimberly A. Rossman, Christy S. Cappelletti, Elizabeth A. Duncan, Jack S. Nyberg, Paul M. Dorinsky   +8 more
doaj   +3 more sources

COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA

Архивъ внутренней медицины, 2016
There were examined 86 patients aged 20 to 65 years with a diagnosis of bronchial asthma (BA). The objective is to evaluate the level of disease control, to study the effectiveness, safety and usability when used Foster (beclomethasone dipropionate and ...
V. A. Nikitin, O. A. Lepuchova, L. V. Vasilieva, E. P. Karpuchina   +3 more
doaj   +3 more sources

NMR characterisation of dynamics in solvates and desolvates of formoterol fumarate [PDF]

Physical Chemistry Chemical Physics, 2013
Solid-state NMR is used to characterise dynamics in the ethanol solvate of the pharmaceutical material formoterol fumarate and its associated desolvate. Jump rates and activation barriers for dynamic processes such as phenyl ring rotation and methyl group rotational diffusion are derived from 1D-EXSY and (13)C spin-lattice relaxation times respectively.
Apperley, D., Markwell, A.F., Frantsuzov, I., Ilott, A.J., Harris, R.K., Hodgkinson, P.   +5 more
openaire   +4 more sources

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD

International Journal of COPD, 2018
Gary T Ferguson,1 Roberto Rodriguez-Roisin,2 Colin Reisner,3,4 Andrea Maes,3 Shahid Siddiqui,4 Ubaldo J Martin4 1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2Universitat de Barcelona, Hospital Clínic-The August ...
Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ   +5 more
doaj   +1 more source

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy

International Journal of COPD, 2017
Santosh Dhungana, Gerard J Criner Department of Thoracic Medicine and Surgery, Temple Lung Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Abstract: Long-acting bronchodilators are the mainstay of the treatment of COPD.
Dhungana S, Criner GJ
doaj   +1 more source

Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management [PDF]

Therapeutic Advances in Respiratory Disease, 2018
Introduction: In recognition of the value of long-term real-world data, a postauthorization safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting β 2 -agonist (LABA) formoterol fumarate (fluticasone/formoterol; Flutiform
Vibeke Backer, Adam Ellery, Sylvia Borzova, Stephen Lane, Magda Kleiberova, Peter Bengtsson, Tadeusz Tomala, Dominique Basset-Stheme, Carla Bennett, Dirk Lindner, Arthur Meiners, Tim Overend   +11 more
doaj   +2 more sources

Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial

Therapeutic Advances in Respiratory Disease, 2008
Formoterol fumarate is a long-acting β 2-agonist that is an effective bronchodilator for the maintenance management of patients with chronic obstructive pulmonary disease.
James F. Donohue, Nicola A. Hanania, Charles Fogarty, Sammy C. Campbell, Mike Rinehart, Kimberly Denis-Mize   +5 more
doaj   +2 more sources

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients [PDF]

Respiratory Medicine, 2008
Nebulized solutions of long-acting bronchodilators provide an alternative to DPI and MDI delivery, particularly for COPD patients unable to use hand-held devices easily or correctly. The long-acting beta2-agonist, formoterol fumarate, is differentiated by its onset of significant bronchodilation within 5 min of administration.
Gross, Nicholas J., Nelson, Harold S., Lapidus, Robert J., Dunn, Leonard, Lynn, Lon, Rinehart, Mike, Denis-Mize, Kimberly   +6 more
openaire   +3 more sources

Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history [PDF]

Respiratory Research
Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis ...
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul Patel   +8 more
doaj   +2 more sources